Clinuvel Pharmaceuticals stock analysis
Clinuvel Pharmaceuticals (CLVLF) Stock Price & Analysis
CLVLF Stock Chart & Stats
- Day’s Range
- $4.54 - $5.09
- 52-Week Range
- $4.53 - $8.93
- Previous Close
- $4.87
- Volume
- N/A
- Average Volume (3M)
- 1,262
- Market Cap
- $243.15M
- Enterprise Value
- $272.15M
- Total Cash (Recent Filing)
- $252.06M
- Total Debt (Recent Filing)
- $1.94M
- Price to Earnings (P/E)
- 10.6
- Beta
- 0.06
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.17
- Last Dividend Ex-Date
- Sep 04, 2026
- Dividend Yield
- 0.75%
Bulls Say, Bears Say
Bulls Say
Profitable SCENESSE Franchise
A decade of uninterrupted profitability demonstrates a proven commercial model and reduces dependence on unvalidated future products. Record SCENESSE treatment volumes and revenue above AUD 100 million provide an established earnings base that can support continued investment and expansion over the next several years.
Debt-free Balance Sheet And Cash Generation
Substantial cash reserves and a debt-free balance sheet give Clinuvel financial flexibility to fund clinical development, infrastructure and commercialization without relying on external financing. This strengthens resilience during market or development setbacks and preserves management’s ability to invest for durable growth.
R&D Pipeline And Platform Expansion
Material reinvestment in multiple programs creates opportunities to broaden the company beyond its established EPP franchise. Progress in vitiligo, NEURACTHEL and the controlled-release peptide platform could add future products and expand the addressable market, while the Singapore facility increases development capacity.
Bears Say
Revenue And Margin Deterioration
The return to negative revenue growth and the pronounced gross-margin reset indicate that recent earnings quality is weaker than the historical trend. If this reflects pricing, product mix or cost pressure rather than a temporary fluctuation, it could constrain profitability and reduce funds available for pipeline investment.
Competitive Pressure In EPP
Free competing treatments can delay or displace SCENESSE use and make patient acquisition more difficult in the U.S., even if the pressure is linked to clinical trials. Continued competition could limit treatment-volume growth and require greater commercial effort to protect the established EPP franchise.
Long And Uncertain Regulatory Timelines
The extended CUV107 timetable delays clarity on the vitiligo opportunity and keeps future expansion dependent on lengthy clinical and regulatory execution. Additional FDA education and engagement add uncertainty to approval timing, potentially postponing diversification beyond SCENESSE for several years.
Clinuvel Pharmaceuticals News
CLVLF FAQ
What was Clinuvel Pharmaceuticals ’s price range in the past 12 months?
What is Clinuvel Pharmaceuticals ’s market cap?
When is Clinuvel Pharmaceuticals ’s upcoming earnings report date?
How were Clinuvel Pharmaceuticals ’s earnings last quarter?
Is Clinuvel Pharmaceuticals overvalued?
Does Clinuvel Pharmaceuticals pay dividends?
What is Clinuvel Pharmaceuticals ’s EPS estimate?
How many shares outstanding does Clinuvel Pharmaceuticals have?
What happened to Clinuvel Pharmaceuticals ’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals ?
What is the TipRanks Smart Score and how is it calculated?
Clinuvel Pharmaceuticals Stock Smart Score
Company Description
Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Philippe Jacques Wolgen
- Employees
- 16
- Website
- www.clinuvel.com
- Address
- 535 Bourke Street, Melbourne, VIC, 3000, AU
Clinuvel Pharmaceuticals (CLVLF) Earnings & Revenues
CLVLF Company Deck
CLVLF Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, emphasizing a 10th consecutive year of profitability, revenue above AUD 100 million, strong margins, increasing cash reserves, a debt-free balance sheet, continued R&D investment, and multiple strategic and clinical catalysts. The main challenges were moderated U.S. sales due to competitor trial programs, currency translation effects, a long vitiligo development timeline, continued FDA engagement requirements, and PhotoCosmetics not yet being ready for launch.
View all CLVLF earnings summariesCLVLF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |








